The UK and US have signed a landmark commercial pact that will ensure no duties on UK medicine shipments going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these vital products will be held at nothing for a period of 36 months.
This deal follows earlier threats to significantly raise tariffs on branded drug products, with potential rates discussed reaching 100%.
"This arrangement between the UK strengthens the international landscape for cutting-edge drugs and brings much-needed fairness to transatlantic pharmaceutical trade," an announcement noted.
Commercial Significance
Pharmaceuticals represent one of the UK's largest exports to the United States, which is by far the largest destination for large UK drugmakers.
Export figures reveal that in the one-year period leading up to last September, the UK exported medicines totaling over eleven billion pounds to the US. This amount made up a significant portion of all goods exports in that timeframe.
"This deal protects employment, boosts capital expenditure and paves the way for the UK to become a international leader for medical research," a minister commented.
Specific UK Commitments
The pact involves several notable pledges from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase total health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. In the past, rebates were more than 20%.
Industry Background
The pact takes place against a long-running tension between the drug companies and the British authorities over spending levels and regulatory access.
These tensions were intensified by arguments that US patients were paying significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several large pharmaceutical investments in the UK have been delayed or scrapped, while substantial funding commitments have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the past decade.
